3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models

Citations Over TimeTop 10% of 2012 papers

Abstract

The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression. We optimized a new inhibitor scaffold, 3-amido-5-cyclopropylpyrrolopyrazines, to a potent example with reasonable kinome selectivity, including selectivity for JAK3 versus JAK1, and good biopharmaceutical properties. Evaluation of this analogue in cellular and in vivo models confirmed functional selectivity for modulation of a JAK3/JAK1-dependent IL-2 stimulated pathway over a JAK1/JAK2/Tyk2-dependent IL-6 stimulated pathway.

Related Papers

• → A child with severe juvenile dermatomyositis treated with ruxolitinib(2018)80 cited
• → A child with severe juvenile dermatomyositis treated with ruxolitinib(2018)6 cited
• → 1060 JAK inhibitor CTP-543: Modeled exposure-response profile suggests improved therapeutic window(2018)1 cited
• → OP0155 Development of A JAK3 Specific Inhibitor Clinical Candidate: Functional Differentiation of JAK3 Selective Inhibition over PAN-JAK or JAK1 Selective Inhibition(2016)
• → Phase 1 trial of ruxolitinib, temozolomide, and radiation in high-grade gliomas.(2022)